Baidu
map

ANN RHEUM DIS:系统性红斑狼疮的卒中情况—一项基于瑞典人群的队列研究

2017-04-14 xiangting MedSci原创

SLE患者缺血性卒中的相对风险是一般人群的两倍以上,重要的是在SLE诊断后第一年内相对风险最高。

近日风湿病权威杂志ANN RHEUM DIS上发表了一篇文章,旨在探讨根据年龄、性别和狼疮诊断时间系统性红斑狼疮(SLE)缺血性和出血性卒中的发生与一般人群的区别。

研究人员从瑞典国家患者登记册(NPR)中入组SLE成年患者共3390名,在总人口登记册中找到16730名年龄,性别和居住地相匹配的正常人。对入组对象进行追踪,观察终点是死亡、2013年12月份、移民或卒中(根据NPR、死因登记册和卒中登记册进行确定)。将SLE患者与非SLE患者进行比较,估计卒中的发生率、发生率差异和HR,并按性别、年龄和诊断后时间进行分层。

研究人员发现SLE中有126例出现卒中,一般人群中有304例出现卒中。与一般人群相比,SLE患者的缺血性卒中发生率增加了两倍(HR 2.2;95%CI为1.7-2.8)。脑内出血HR为1.4(95%CI为0.7-2.8)。根据性别和年龄进行效应修正后发现,女性和<50岁的个体HRs最高。缺血性卒中的HR在随访的第一年中最高(3.7; 95%CI为2.1-6.5)。

SLE患者缺血性卒中的相对风险是一般人群的两倍以上,重要的是在SLE诊断后第一年内相对风险最高。本研究为风湿病科医师提供了可供筛选的危险因素和进行干预的时机。

原始出处:

Elizabeth V Arkema, et al. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. ANN RHEUM DIS. 11 April 2017. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012203, encodeId=d006201220320, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 09 10:32:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016955, encodeId=d3e42016955e0, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 05:32:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387188, encodeId=52bc138e18889, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436094, encodeId=047b1436094d0, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012203, encodeId=d006201220320, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 09 10:32:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016955, encodeId=d3e42016955e0, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 05:32:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387188, encodeId=52bc138e18889, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436094, encodeId=047b1436094d0, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012203, encodeId=d006201220320, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 09 10:32:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016955, encodeId=d3e42016955e0, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 05:32:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387188, encodeId=52bc138e18889, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436094, encodeId=047b1436094d0, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012203, encodeId=d006201220320, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jan 09 10:32:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016955, encodeId=d3e42016955e0, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Oct 12 05:32:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387188, encodeId=52bc138e18889, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436094, encodeId=047b1436094d0, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 16 01:32:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-04-16 zhouqu_8

相关资讯

Heart:系统性红斑狼疮患者心力衰竭的发生率及风险如何?

相比于普通人群,系统性红斑狼疮患者有较高的心力衰竭发生风险和严重的心血管风险谱,这些结果需要进一步通过前瞻性研究来证实。

2016EULAR循证建议——系统性红斑狼疮和/或抗磷脂综合征女性患者计划生育,辅助生殖,妊娠和更年期管理及健康发布

2016年7月,欧洲抗风湿病联盟(EULAR)发布了系统性红斑狼疮和/或抗磷脂综合征女性患者计划生育,辅助生殖,妊娠和更年期管理及健康建议,建议涉及的内容包括:优生咨询和危险分层,避孕措施,生育能力下降的危险因素,维持生育能力,人工授精,系统性红斑狼疮疾病活动期孕产妇生物标志物检测,孕期监测,药物预防,妊娠期辅助治疗,更年期激素替代疗法,恶性肿瘤筛查,HPV疫苗接种。全文获取:下载地址:指南下载&

Nat Genet:GWAS的荟萃分析发现10个新的系统性红斑狼疮位点

来自安徽医科大学、伦敦大学国王学院、香港大学等处的研究人员报告称,他们对中国人和欧洲人进行了全全基因组关联荟萃分析,鉴别出了与系统性红斑狼疮相关的10个新位点。研究结果发布在7月11日的《自然遗传学》(Nature Genetics)杂志上。 安徽医科大学的崔勇(Yong Cui)教授,伦敦大学国王学院的Timothy J Vyse教授,及香港大学的香港大学杨万岭(Wanling Yang)

系统性红斑狼疮与感染之间的秘密

一项来自协和医院的回顾性研究分析了过去26年间在协和医院狼疮患者的死亡原因,发现在268名死亡患者中继发感染的患者有101人,达到37.3%。进一步分析死亡原因构成比的变化发现在20世纪80年代,患者最常见的死亡原因是肾脏累及,而进入21世纪后继发感染逐渐成为狼疮患者死亡最常见的原因。因此,对于风湿科医生来讲了解狼疮与感染相关知识十分必要。本文将从如下四个方面介绍狼疮与感染的关系、鉴别及狼疮继

Nat Med:北大栗占国教授发现低剂量IL-2能治疗系统性红斑狼疮

IL-2是免疫系统中的一类细胞生长因子,能调控免疫系统中白血球的细胞活性。?北京大学人民医院科研团队近期在国际上首次应用低剂量白细胞介素-2(IL-2)治疗系统性红斑狼疮,与传统的免疫治疗相比,这项低剂量IL-2治疗并未增加感染的风险。系统性红斑狼疮是一种严重的系统性自身免疫性疾病。该病患病率高、预后差,严重威胁患者的生活质量。目前该病的治疗方案为激素和免疫抑制剂治疗,常伴有感染和肿瘤等多种不良反

狼疮新药进展!葛兰素史克向美国和欧盟提交皮下注射剂型狼疮药Benlysta(每周一次)上市申请

英国制药巨头葛兰素史克(GSK)近日宣布已向美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)提交皮下注射剂型(SC)狼疮药物Benlysta(belimumab,贝利木单抗)治疗活动性、抗体阳性系统性红斑狼疮(SLE)的监管申请文件,包括:(1)向FDA提交了皮下注射剂型Benlysta的生物制品许可申请(BLA),寻求批准用于正接受标准疗法的活动性、抗体阳性SLE成人患者;(2)向EMA

Baidu
map
Baidu
map
Baidu
map